Expand BMEA Menu
BMEA MENU

BMEA Latest Press Releases

-- January 12, 2026 --

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones Globe Newswire 8:00 AM

-- December 17, 2025 --

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 9, 2025 --

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 Globe Newswire 6:35 PM

-- December 5, 2025 --

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Globe Newswire 7:00 AM

-- December 1, 2025 --

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Globe Newswire 4:10 PM
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- November 24, 2025 --

Biomea Fusion to Participate at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- November 10, 2025 --

Biomea Fusion to Participate at Jefferies London Healthcare Conference Globe Newswire 7:00 AM

-- November 5, 2025 --

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek 2025 Globe Newswire 7:00 AM

-- November 4, 2025 --

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights Globe Newswire 4:05 PM

-- October 30, 2025 --

Biomea Fusion to Present Poster Presentations at ObesityWeek2025 Globe Newswire 8:00 AM

-- October 27, 2025 --

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist Globe Newswire 8:00 AM

-- October 21, 2025 --

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series Globe Newswire 7:05 PM

-- October 7, 2025 --

Biomea Fusion Announces Pricing of Public Offering of Securities Globe Newswire 8:00 AM

-- October 6, 2025 --

Biomea Fusion Announces Proposed Public Offering of Securities Globe Newswire 4:18 PM
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations Globe Newswire 4:03 PM

-- October 1, 2025 --

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- September 16, 2025 --

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes